Common Defective Medical Devices and Related Injuries
Medical devices range from simple tongue depressors to implanted cardiac defibrillators. When a device fails inside the body, the consequences can be severe. Several categories of devices have generated significant litigation across Louisiana and the rest of the country.
Metal on metal hip implants have caused metallosis, a condition where cobalt and chromium particles shed into surrounding tissue. Patients with these implants have experienced chronic pain, bone deterioration, and the need for early revision surgery. Hernia mesh products have caused bowel obstructions, infections, mesh migration, and chronic pain that persists even after removal. IVC filters, designed to catch blood clots traveling toward the lungs, have fractured inside patients, perforated blood vessel walls, and migrated to the heart.
Defective pacemakers and defibrillators have delivered inappropriate shocks, failed to pace correctly, or required premature replacement due to battery defects. Knee replacement systems with polyethylene liner failures have loosened prematurely, causing bone loss and requiring revision surgery within years of the original procedure. Surgical stapling devices have misfired during operations, causing internal bleeding and tissue damage.
Each of these device categories involves distinct engineering failures, regulatory histories, and injury patterns. The type of device determines which legal theories apply and what evidence is needed to prove the claim.
FDA Regulation and Its Limits
The FDA classifies medical devices into three categories based on risk. Class I devices pose minimal risk and include items like bandages and examination gloves. Class II devices carry moderate risk and include powered wheelchairs, pregnancy tests, and some surgical instruments. Class III devices pose the greatest risk and include implantable pacemakers, hip replacements, and heart valves.
Most Class II devices reach the market through the 510(k) clearance process. This process requires manufacturers to demonstrate that their device is "substantially equivalent" to a device already on the market. The FDA does not require clinical trials for 510(k) clearance. The manufacturer compares its product to a predicate device and submits technical data. This means many implanted devices enter the market without independent testing on human patients.
Class III devices require Premarket Approval, known as PMA. This is a more rigorous process that includes clinical trial data, manufacturing inspections, and ongoing post market surveillance. However, PMA approval does not guarantee safety. The FDA has approved devices that later proved defective after thousands of patients received them.
The FDA maintains an adverse event reporting database called MAUDE. Manufacturers must report device malfunctions, serious injuries, and deaths. Hospitals and medical facilities must report device related deaths. Individual patients and physicians may also submit voluntary reports. This database often reveals patterns of failure before a formal recall occurs.
Louisiana Products Liability Claims for Medical Devices
Louisiana governs product defect claims through the Louisiana Products Liability Act, La. R.S. 9:2800.51 through 9:2800.59. The LPLA is the exclusive remedy against manufacturers for damage caused by their products. A claimant must prove four elements: the product had a condition that made it unreasonably dangerous, the condition existed at the time it left the manufacturer's control, the condition caused the damage, and the damage could have been prevented by an alternative design or adequate warning.
The LPLA recognizes four theories of liability. A construction or composition defect exists when the device deviates from the manufacturer's own specifications or standards. A design defect exists when an alternative design would have prevented the damage and the risk of the existing design outweighs its utility. An inadequate warning claim applies when the manufacturer failed to provide adequate instructions or warnings about a risk associated with the device. An express warranty claim applies when the manufacturer made a specific representation about the device that proved false.
For medical devices, the learned intermediary doctrine plays a significant role. Under this doctrine, the manufacturer's duty to warn runs to the prescribing physician rather than directly to the patient. The reasoning is that the physician serves as an intermediary who evaluates the risks and benefits for each patient. Louisiana courts have applied this doctrine in medical device cases. A manufacturer that provides adequate warnings to the prescribing physician may have a defense against failure to warn claims, even if the patient never received those warnings directly.
This doctrine does not protect manufacturers in every situation. If the manufacturer's warnings to the physician were themselves inadequate, misleading, or failed to disclose known risks, the defense fails. If the manufacturer marketed the device directly to consumers, the doctrine may not apply.
Federal Preemption and State Claims
Federal preemption is a critical issue in medical device litigation. The Medical Device Amendments of 1976 include a preemption clause in Section 360k(a) that prohibits states from imposing requirements that are "different from, or in addition to" federal requirements for devices that have gone through certain FDA processes.
The U.S. Supreme Court addressed this issue in Riegel v. Medtronic, Inc. (2008). The Court held that state law claims against manufacturers of PMA approved devices are preempted when those claims would impose requirements beyond what the FDA required during the PMA process. This decision significantly limited state court litigation for Class III devices that received full PMA approval.
However, preemption does not apply the same way to 510(k) cleared devices. In Medtronic, Inc. v. Lohr (1996), the Court held that 510(k) clearance does not trigger preemption because the clearance process does not impose device specific federal requirements. This distinction matters. Many of the devices that have caused widespread injuries, including certain hernia mesh products and IVC filters, reached the market through the 510(k) pathway. State law claims against these devices generally survive preemption challenges.
Even for PMA approved devices, a narrow category of claims may survive. "Parallel claims" allege that the manufacturer violated both state law and federal requirements simultaneously. If a manufacturer deviated from its own FDA approved specifications during production, a state law claim based on that same deviation may proceed. These claims require specific evidence of federal regulatory violations.
Building a Defective Device Case in Louisiana
Documenting a defective medical device claim requires specific categories of evidence. Medical records must establish when the device was implanted, what symptoms developed, and what treatment was required after the failure. Operative reports from any revision or removal surgery describe the condition of the failed device.
FDA records provide important context. MAUDE database reports may show that the same device model caused similar injuries in other patients. FDA warning letters to the manufacturer may document manufacturing violations. Device recall notices establish that the FDA or the manufacturer acknowledged a safety problem. The device's 510(k) summary or PMA approval documents reveal what the manufacturer told the FDA about the device's safety profile.
The physical device itself, if recovered during revision surgery, is important evidence. The device should be preserved rather than discarded after removal. Metallurgical analysis or engineering inspection of the failed device can identify the specific defect, whether a fracture, corrosion, wear pattern, or material failure.
Louisiana law sets a prescriptive period for filing personal injury claims. For injuries arising from incidents before July 1, 2024, the prescriptive period is one year from the date of discovery under La. C.C. art. 3492. For injuries arising from incidents on or after July 1, 2024, the prescriptive period is two years. In defective device cases, discovery may occur later than the implantation date. A patient may not know the device failed until symptoms appear or imaging reveals the problem. The prescriptive period begins when the patient knew or should have known about the injury and its connection to the device.
Louisiana's comparative fault system also applies. For incidents on or after January 1, 2026, a claimant who bears 51 percent or more of the fault cannot recover damages. In most defective device cases, the manufacturer bears the primary fault, but defendants may argue that the implanting surgeon or the patient contributed to the injury. Fault allocation among multiple parties, including the manufacturer, the surgeon, and the hospital, is determined by the jury or judge at trial.
Cases filed in Caddo Parish proceed through the First Judicial District Court. Federal court is also an option when the manufacturer is based outside Louisiana and the amount in controversy exceeds $75,000, which is common in device cases. Some defective device claims are consolidated into multidistrict litigation in federal court, where pretrial proceedings are handled together before cases return to their home courts for trial.